Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,617.10 -329.83 (-0.85%) Hang Seng
19,198.46 -22.16 (-0.12%) FTSE 100
8,375.37 -41.08 (-0.49%) Bitcoin USD
69,710.75 -1,292.05 (-1.82%) CMC Crypto 200
1,469.86 -56.56 (-3.71%)
SNY Jan 2025 52.500 call
| Previous close | 2.7100 |
| Open | 2.5500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 52.50 |
| Expiry date | 2025-01-17 |
| Day's range | 2.5500 - 2.7100 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Associated Press Finance
Hawaii court orders drug companies to pay $916 million in Plavix blood thinner lawsuit
A Hawaii court has ordered the manufacturers and distributors of the blood thinner Plavix to pay the state a combined $916 million after finding the companies failed to disclose the efficacy and safety of the medication, the state attorney general said Tuesday. The judgement was issued against Bristol Myers Squibb Company and three U.S.-based subsidiaries of French pharmaceutical company Sanofi. Bristol Myers Squibb and Sanofi said in a joint statement they disagreed with the penalty and plan to appeal.
ZacksSanofi (SNY) Signs Deal for AI-Powered Drug Development
Sanofi (SNY) inks collaboration deal with Formation Bio and OpenAI to build AI-powered software to advance drug development and create new medicines.
BenzingaChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development
Tuesday, French drugmaker Sanofi SA (NASDAQ:SNY) announced its collaboration with OpenAI and Formation Bio to accelerate drug development projects. Also Read: Drugmaker Sanofi’s Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings. Sanofi said the partnership with OpenAI will allow it to access proprietary data to develop AI models for its biopharma models, while Formation Bio will provide additional engineering resources. The three teams will combine data, software, and tuned models t
